Open AccessLeft Atrial Enlargement in the Early Stage of Hypertensive Heart Disease: A Common But Ignored Condition
Author(s) -
Su Guanhua,
Cao Heng,
Xu Sudan,
Lu Yongxin,
Shuai Xinxin,
Sun Yufei,
Liao Yuhua,
Li Jingdong
Publication year - 2014
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12282
Subject(s) - medicine , left atrial enlargement , cardiology , heart failure , ejection fraction , hypertensive heart disease , body mass index , waist , heart failure with preserved ejection fraction , bayesian multivariate linear regression , heart disease , atrial fibrillation , linear regression , sinus rhythm , machine learning , computer science
How to identify the early signs of hypertensive heart disease is the key to block or reverse the process of heart failure. The aim of this study was to evaluate the predictive value of left atrial ( LA ) enlargement in the early stage of hypertensive heart disease and to explore the correlations between LA enlargement and heart failure with normal ejection fraction ( HF n EF ), as well as the metabolic syndrome (MetS). Baseline clinical characteristics, biochemical indices, electrocardiographic and echocardiographic data were collected from 341 consecutive patients with essential hypertension. Among those patients, LA enlargement was more frequently presented than LV enlargement (57.2% vs 17.9%). Compared with patients without HF n EF , the prevalence of LA enlargement was higher in patients with HF n EF (82.9% vs 49.0%, P <.0001). From grade 2 to grade 3 hypertension, LA size was significantly larger in patients with MetS ( P <.01) than those without. Multivariate linear regression analyses showed that age, body mass index, waist circumference, triglyceride level, and left ventricular diameter were independent predictors of LA enlargement. The simple measurement for identification of LA enlargement potentially allows early recognition of those patients at risk for heart failure, particularly among patients with MetS.